|
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
A 10-week Randomized, Double-blind, Placebo-controlled, Prospective, International, Multicentre, Phase IIa Study of S42909 on Leg Ulcer Healing.
Dose-response relationship study of S42909 on leg ulcer healing after oral repeated administration in patients with active venous leg ulcer.
100 Clinical Results associated with ILKOS THERAPEUTICS, Inc.
0 Patents (Medical) associated with ILKOS THERAPEUTICS, Inc.
100 Deals associated with ILKOS THERAPEUTICS, Inc.
100 Translational Medicine associated with ILKOS THERAPEUTICS, Inc.